Clinical and Translational Allergy

POSTER PRESENTATION Open Access

# A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies

Peter Hellings[1*], Claus Bachert[2], Ralph Mösges[3], Glenis Scadding[4], Ullrich Munzel[5], Wytske Fokkens[6]

*From* The 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015) Stockholm, Sweden. 19-21 February 2015

## Background

The efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride [AZE] and fluticasone propionate [FP] in an advanced delivery system) in providing overall nasal and ocular symptom relief vs AZE, FP or placebo (PLA) has been assessed.

## Methods

Six hundred and ten moderate-to-severe SAR patients (≥12 yrs) were randomized into a double-blind, PLA-controlled, 14-day, parallel-group, trial (NCT00660517) to MP29-02*, AZE, FP or PLA nasal sprays (1 spray/nostril bd; daily dose: AZE=548μg; FP=200μg) [1]. Change from baseline (CFB) in reflective total of 7 symptom scores (rT7SS; AM + PM, max=42) was assessed post-hoc. CFB in rT7SS and each nasal (congestion, itching, rhinorrhea, sneezing) and ocular symptom (itching, redness, watering; max=6 each) was assessed over time.

## Results

Overall, MP29-02* patients showed greater reduction in rT7SS vs FP, AZE & PLA (relative diff: 52% to FP (p=0.0013), 56% to AZE (p=0.0004)) evident from treatment day 1 vs FP (p=0.0072), AZE (p=0.0336) or PLA (p<0.0001) and sustained for 14 days. The level of relief achieved by MP29-02* patients on Day 2 (-5.52) was not achieved before Day 5 by FP patients or Day 8 by AZE patients. This pattern of rapid, sustained and superior symptom relief by MP29-02* was observed for each nasal and ocular symptom, which was not the case with FP and AZE. MP29-02* provided significantly superior nasal congestion relief than FP or AZE from Day 2; the level of congestion relief provided by MP29-02* on Day 2 (-0.77) was not achieved before Day 6 and Day 9 for FP and AZE, respectively. MP29-02* provided significantly superior ocular itching relief vs FP from Day 2 and vs AZE from Day 3; the ocular itch relief provided by MP29-02* on Day 2 (-0.77) was not achieved before Day 10 for FP-patients. Similarly, the level of ocular itch relief provided by MP29-02* on Day 3 (-1.06) was not achieved by AZE-patients before Day 11.

## Conclusion

The consistent and rapid effect in alleviating all nasal and ocular symptoms is unique to MP29-02* and contributes to its superiority over AZE and FP. The time advantage over firstline therapy in achieving significant relief and sustained effect should improve patient concordance. MP29-02* is considered a new standard of care in AR.

* Dymista

**Authors' details**
[1]University Hospitals Leuven, Dept of Otorhinolaryngology, Head & Neck Surgery, Leuven, Belgium. [2]Ghent University Hospital, Department of Oto-Rhinolaryngology, Ghent, Belgium. [3]University of Cologne, IMSIE, Cologne, Germany. [4]The Royal National Throat Nose and Ear Hospital, London, UK. [5]Meda, Corporate Clinical Affairs, Bad Homburg, Germany. [6]Academic Medical Center, Department of Otorhinolaryngology, Amsterdam, Netherlands.

Published: 26 June 2015

**Reference**

1. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, *et al*: . *Int Arch Allergy Immunol* 2013, **161(4)**:369-77.

doi:10.1186/2045-7022-5-S4-P34
**Cite this article as:** Hellings *et al.*: A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies. *Clinical and Translational Allergy* 2015 **5**(Suppl 4):P34.

[1]University Hospitals Leuven, Dept of Otorhinolaryngology, Head & Neck Surgery, Leuven, Belgium
Full list of author information is available at the end of the article